Prevalencia de la captación cardíaca incidental en la gammagrafía ósea con tc99m-hmdp en la Fundación Santa Fe de Bogota 2018-2023

dc.contributor.advisorLineros Montañez , Alberto
dc.contributor.advisorGonzalez Robledo, Gina
dc.contributor.authorIsaac de Medeiros, Rafael Havid
dc.contributor.authorRodriguez Pulido, Astrid Lorena
dc.date.accessioned2024-08-02T16:09:00Z
dc.date.available2024-08-02T16:09:00Z
dc.date.issued2024-07
dc.description.abstractLa amiloidosis cardiaca (AC) es una afección progresiva y, a menudo, subdiagnosticada. Este estudio tiene como objetivo determinar la prevalencia de captación cardíaca incidental de Tc99m-HMDP en gammagrafía ósea en pacientes de 65 años o más en la Fundación Santa Fe de Bogotá entre 2018 y 2023. Se realizó un estudio observacional retrospectivo en pacientes de 65 años o más a los que se les realizó gammagrafía ósea con Tc99m-HMDP durante el período de estudio. Se excluyeron los estudios solicitados bajo sospecha de AC. Se evaluó la prevalencia de captación cardíaca estratificada por el grado de Perugini y se correlacionó con las características demográficas y clínicas. Se evaluaron 1410 pacientes individuales, 19 (1,35%) presentaron captación cardíaca, correspondiendo 10 (0,71%) a grado 2 o 3 de Perugini. La prevalencia aumentó significativamente con la edad y fue mayor en hombres. Los pacientes con captación cardíaca eran significativamente mayores (82 ± 5,55 años) que los que no tenían captación (75 ± 4,13 años) (p = 0,00002). La prevalencia de cualquier captación cardíaca fue del 2,04% (12/589) en los hombres y del 0,85% (7/821) en las mujeres. Conclusión: La prevalencia de ATTR cardíaca aumenta con la edad y es ligeramente mayor en los hombres en el contexto de este estudio. Estos resultados resaltan la importancia de reconocer y considerar la ATTR en pacientes ancianos sometidos a gammagrafía ósea por indicaciones no cardíacas para garantizar una adecuada atención y seguimiento clínico.
dc.description.abstractenglishCardiac amyloidosis (CA) is a progressive and often underdiagnosed condition. This study aims to determine the prevalence of incidental cardiac uptake of Tc99m-HMDP in bone scintigraphy among patients aged 65 years or more at Fundación Santa Fe de Bogotá from 2018 to 2023. A retrospective observational study was conducted on patients aged 65 and older who underwent Tc99m-HMDP bone scintigraphy during the study period. Scans requested in suspicion of CA were excluded. The prevalence of cardiac uptake stratified by Perugini grade was assessed and correlated with demographic and clinical characteristics. 1410 individual patients were assessed, 19 (1.35%) showed cardiac uptake, with 10 (0.71%) corresponding to Perugini grade 2 or 3. Prevalence increased significantly with age and was higher in males. Patients with cardiac uptake were significantly older (81.89 ± 5.55 years) than those with no uptake (74.62 ± 4.13 years) (p = 0.00002). The prevalence of any cardiac uptake was 2.04% (12/589) in males and 0.85% (7/821) in females. Conclusion: The prevalence of cardiac ATTR increases with age and is slightly higher in males within the context of this study. These results highlight the importance of recognizing and considering ATTR in elderly patients undergoing bone scintigraphy for non-cardiac indications to ensure adequate care and follow-up.
dc.description.degreelevelEspecializaciónspa
dc.description.degreenameEspecialista en Cardiología de Adultosspa
dc.description.sponsorshipFundacion Santa Fe de Bogotá
dc.format.mimetypeapplication/pdf
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/12803
dc.language.isoes
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.grantorUniversidad El Bosquespa
dc.publisher.programEspecialización en Cardiología Adultosspa
dc.relation.references1. Schleiden M, Schwann T. Klassische Schriften der ZellenlehreDeutsch Harri GmbH. 1987th ed. (1-166).
dc.relation.references2. Tomás R. Amiloidosis: una historia convolucionada. 1951st ed. . Ger Life Lett; (66-68; vol. 5).
dc.relation.references3. Virchow R. Cellular pathology. As based upon physiological and pathological histology. Lecture XVI--Atheromatous affection of arteries. 1858. Nutr Rev. 1989 Jan;47(1):23–5.
dc.relation.references4. Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. Circ Res. 2021 May 14;128(10):1554–75.
dc.relation.references5. Toyama BH, Weissman JS. Amyloid structure: conformational diversity and consequences. Annu Rev Biochem. 2011;80:557–85.
dc.relation.references6. Fu Z, Lv J, Gao X, Zhang B, Li Y, Xu X, et al. Research trends and hotspots evolution of cardiac amyloidosis: a bibliometric analysis from 2000 to 2022. Eur J Med Res. 2023 Feb 20;28(1):89.
dc.relation.references7. Otto CM, Freeman RV, Schwaegler RG, Linefsky JP. Echocardiography review guide
dc.relation.references8. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. Guía ESC/EACTS 2021 sobre el diagnóstico y tratamiento de las valvulopatías. Rev Esp Cardiol. 2022 Jun 1;75(6):524.e1-524.e69.
dc.relation.references9. Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018 Oct 2;25(4):215–9
dc.relation.references10. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain J Neurol. 1952 Sep;75(3):408–27.
dc.relation.references11. Rossi GP, Bisogni V, Rossitto G, Maiolino G, Cesari M, Zhu R, et al. Practice Recommendations for Diagnosis and Treatment of the Most Common Forms of Secondary Hypertension. High Blood Press Cardiovasc Prev. 2020 Dec;27(6):547–60.
dc.relation.references12. Sekijima Y, Yazaki M, Ueda M, Koike H, Yamada M, Ando Y. First nationwide survey on systemic wild-type ATTR amyloidosis in Japan. Amyloid. 2018 Jan 2;25(1):8–10.
dc.relation.references13. Koike H, Okumura T, Murohara T, Katsuno M. Multidisciplinary Approaches for Transthyretin Amyloidosis. Cardiol Ther. 2021 Dec;10(2):289–311.
dc.relation.references14. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020 Jul 7;142(1):e7–22.
dc.relation.references15. Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013 Jan;29(1):63–76.
dc.relation.references16. Pozsonyi Z, Peskó G, Takács H, Csuka D, Nagy V, Szilágyi Á, et al. Variant Transthyretin Amyloidosis (ATTRv) in Hungary: First Data on Epidemiology and Clinical Features. Genes. 2021 Aug;12(8):1152.
dc.relation.references17. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232–9.
dc.relation.references18. Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies. Eur J Heart Fail. 2022 Dec;24(12):2342–51.
dc.relation.references19. Treglia G, Martinello C, Dondi F, Albano D, Bertagna F, Rizzo A, et al. Prevalence of Incidental Findings Suspicious for Transthyretin Cardiac Amyloidosis among Patients Undergoing Bone Scintigraphy: A Systematic Review and a Meta-Analysis. J Clin Med. 2023 Sep 1;12(17):5698.
dc.relation.references20. AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021 Nov 1;6(11):1267.
dc.relation.references21. Davies DR, Redfield MM, Scott CG, Minamisawa M, Grogan M, Dispenzieri A, et al. A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2022 Oct 1;7(10):1036.
dc.relation.references22. Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, et al. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC CardioOncology. 2021 Oct 19;3(4):537–46.
dc.relation.references23. Zhou J, Li Y, Geng J, Zhou H, Liu L, Peng X. Recent Progress in the Development and Clinical Application of New Drugs for Transthyretin Cardiac Amyloidosis. J Cardiovasc Pharmacol. 2023 Nov 30;82(6):427–37
dc.relation.references24. Nagano N, Muranaka A, Nishikawa R, Ohwada W, Kouzu H, Kamiyama N, et al. Early Detection of Cardiac Amyloidosis in Transthyretin Mutation Carriers. Int Heart J. 2022;63(1):168–75.
dc.relation.references25. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016 Jun 14;133(24):2404–12.
dc.relation.references26. Miller, Edward J., Einstein, Andrew J. Radiopharmaceutical Supply Disruptions and the Use of 99mTc-99 Hydroxymethylene Diphosphonate as an Alternative to 99mTc-Pyrophosphate for the Diagnosis of Transthyretin Cardiac Amyloidosis: An ASNC Information Statement. 2022 Jun 22 [cited 2023 Feb 27]; Available from: https://zenodo.org/record/6687334
dc.relation.references27. Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail. 2019;6(6):1128–39.
dc.relation.references28. Tomasoni D, Bonfioli GB, Aimo A, Adamo M, Canepa M, Inciardi RM, et al. Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials. Front Cardiovasc Med [Internet]. 2023 May 23 [cited 2024 Jul 22];10. Available from:
dc.relation.references29. Khor YM, Cuddy SAM, Singh V, Falk RH, Di Carli MF, Dorbala S. 99m Tc Bone-Avid Tracer Cardiac Scintigraphy: Role in Noninvasive Diagnosis of Transthyretin Cardiac Amyloidosis. Radiology. 2023 Feb 1;306(2):e221082.
dc.rightsAtribución-NoComercial-CompartirIgual 4.0 Internacionalen
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.localAcceso abiertospa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subjectAmiloidosis cardiaca
dc.subjectTc99m-HMDP
dc.subjectGammagrafía ósea
dc.subjectTranstiretina
dc.subjectAnciano
dc.subjectPrevalencia
dc.subject.keywordsCardiac amyloidosis
dc.subject.keywordsTc99m-HMDP
dc.subject.keywordsBone scintigraphy
dc.subject.keywordsTransthyretin
dc.subject.keywordsElderly
dc.subject.keywordsPrevalence
dc.subject.nlmWG 100
dc.titlePrevalencia de la captación cardíaca incidental en la gammagrafía ósea con tc99m-hmdp en la Fundación Santa Fe de Bogota 2018-2023
dc.title.translatedPrevalence of incidental cardiac uptake in bone scintigraphy with TC99m-hmdp at Fundación Santa Fe de Bogotá 2018-2023
dc.type.coarhttps://purl.org/coar/resource_type/c_7a1f
dc.type.coarversionhttps://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.driverinfo:eu-repo/semantics/bachelorThesis
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.type.localTesis/Trabajo de grado - Monografía - Especializaciónspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Trabajo de grado.pdf
Tamaño:
387.88 KB
Formato:
Adobe Portable Document Format
Bloque de licencias
Mostrando 1 - 3 de 3
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.95 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
No hay miniatura disponible
Nombre:
Carta de Autorización.pdf
Tamaño:
248.92 KB
Formato:
Adobe Portable Document Format
Descripción:
No hay miniatura disponible
Nombre:
Acta de grado.pdf
Tamaño:
164.76 KB
Formato:
Adobe Portable Document Format
Descripción: